$TTNP - Set up for a Growth Stock in 2020 5 X + CandidateI will update this article I just wanted to get the idea down because this is capable of 2-4 x in short amount of time..
So rough notes but wanted to have it documented real time
Analyst have maintained a .75 and 1 target here which is at the very least 3-4 x from current prices.
$TTNP - Going to be a 5-10 X candidate 2020
For a swing trade .
2020 will be the first year company will become a growth stock
Major analyst have a 1 target on this as unlikely FINRA will allow for another RS so soon.
So they have 1 option get the stock over 1... Remember even company has the option doesn't mean FINRA will approve.
Analyst have also maintained a .75 and 1 target here which is at the very least 3-4 x from current prices.
The last Bio tech i posted on went 10x in a short amount of time and $TTNP has tremendous upside going forward as much of bad news is behind them. They laid down the infastructure for growth in 2019 so 2020 should be a growth year.
Sadly, the Opioid crisis isnt going away. $TTNP is positioned to help the fight against the epidemic and should also profit with that endeavor.
$TTNP has 5-10x + potential chart has lots of gaps up
Do your DD , recent board appointment and all the ground work laid in 2019 for it to become a growth stock in 2020.
My thoughts ..
TTNP is at .20 now
Opioids
Things are looking up for Johnson & JohnsonJohnson & Johnson beat Wall Street's earnings expectations yesterday and raised its full-year guidance. The company has also been steadily settling opioid lawsuits, with another settlement rumored to be in the works soon. JNJ is rated highly undervalued by S&P Capital IQ, and its post-earnings run looks to be the slow, steady kind rather than a big spike. That's what I like to see. I've picked up a little JNJ and plan to ride it up to at least the 139.50 resistance level. I'm considering a long-term hold, although the political risk makes me cautious about this sector going into an election year.
J&J vs opioids (Johnson is winning)Fundamental analysis
In one of the first state opioid cases, an Oklahoma judge ruled against Johnson & Johnson, awarding the state $572 million, well below the over $17 billion the state was seeking in damages.
Meaning... out of the 17 billion, they lost only 3.36%, and they expect to appeal the case, probably lowering this amount.
Technical analysis
On a technical analysis, I still think the risk reward ratio is too small to enter a position now. But technicals are good (not great). So I am keeping this on my watchlist.